12 filings
8-K
SLRN
Acelyrin Inc
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
8-K
SLRN
Acelyrin Inc
28 Mar 24
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
4:08pm
8-K
SLRN
Acelyrin Inc
20 Mar 24
Rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile
7:04am
8-K
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
SLRN
Acelyrin Inc
20 Dec 23
Departure of Directors or Certain Officers
4:38pm
8-K
ahjh lwav6h3
27 Nov 23
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
4:31pm
8-K
8vkrpoqzce7x0
7 Nov 23
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
4:23pm
8-K
s98c1nlc9ua
21 Aug 23
Departure of Directors or Certain Officers
4:03pm
8-K
ermps1gs
14 Aug 23
ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights
4:22pm
8-K
8c6dfo
2 Aug 23
Departure of Directors or Certain Officers
5:05pm
8-K
ieeyfln3r0f94o3sx
15 Jun 23
ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights
4:22pm
8-K
joowe2e3o6698co
9 May 23
ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:16pm
- Prev
- 1
- Next